

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6606)**

**(1) RESUMPTION GUIDANCE; AND**  
**(2) CONTINUED SUSPENSION OF TRADING**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated March 28, 2024 in relation to the trading halt in the shares of the Company on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 9:00 a.m. on March 28, 2024; (ii) the announcement of the Company dated March 28, 2024 in relation to, among others, the delay in publication of the 2023 Annual Results (the “**March 28 Announcement**”); and (iii) the announcement of the Company dated April 8, 2024 in relation to, amongst others, the updates on the Investigation (the “**April 8 Announcement**”).

Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the March 28 Announcement and/or the April 8 Announcement.

**RESUMPTION GUIDANCE**

On May 23, 2024, the Company received a letter from the Stock Exchange setting out the guidance for the resumption of trading in the shares of the Company (collectively, the “**Resumption Guidance**”). Pursuant to the Resumption Guidance, the Company shall:

- (i) publish all outstanding financial results required under the Listing Rules and address any audit modifications;
- (ii) conduct an appropriate independent forensic investigation into the audit issues (including (a) all the concerns raised by the Auditor about the validity and commercial substance of certain sales transactions and selling and marketing expenses of the Company (“**Audit Identified Issues**”); (b) allegations in two short-selling reports against the Group published in 2023; and (c) additional issues raised by the Auditor in relation to the Audit Identified Issues), announce the findings, assess the impact and take appropriate remedial actions;

- (iii) demonstrate that there is no reasonable regulatory concern about the management integrity and/or the integrity of any persons with substantial influence over the Company's management and operations, which may pose a risk to investors and damage market confidence;
- (iv) conduct an independent internal control review and demonstrate that the Company has in place adequate internal controls and procedures to comply with the Listing Rules;
- (v) demonstrate the Company's compliance with Rule 13.24 of the Listing Rules; and
- (vi) inform the market of all material information for the Shareholders and other investors to appraise its position.

It is stated in the Resumption Guidance that the Company must meet all resumption guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange's satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. The Stock Exchange further indicated that it may modify or supplement the Resumption Guidance if the Company's situation changes.

Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on September 27, 2025. If the Company fails to remedy the issues causing its trading suspension, fulfill the resumption guidance and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares by September 27, 2025, the Listing Division will recommend the Listing Committee to proceed with the cancellation of the Company's listing. Under Rules 6.01 and 6.10 of the Listing Rules, the Stock Exchange also has the right to impose a shorter specific remedial period, where appropriate. It is stated in the Resumption Guidance that the Company must announce its first quarterly update on or before June 28, 2024 and every 3 months from that date until resumption or cancellation of listing (whichever is earlier). The Company must also comply with the Listing Rules and all applicable laws and regulations in Hong Kong and the Cayman Islands (being its place of incorporation) before resumption.

The Company is taking appropriate steps to comply with the Resumption Guidance and will seek to resume trading of its shares as soon as possible. The Company will keep the Shareholders and potential investors informed of the latest status and development of the Company, as and when appropriate, as well as publish quarterly updates on its development pursuant to Rule 13.24A of the Listing Rules.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**New Horizon Health Limited**  
**Mr. YeQing ZHU**  
*Chairman*

Hong Kong, May 28, 2024

*As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Prof. Hong WU, Dr. Donald Kwok Tung LI, Mr. Lau Ngai Kee Ricky and Ms. Ng Weng Sin as independent non-executive Directors.*